Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial

TODAY Study Group, Jane Lynch, Laure El, Lynda Fisher, Samuel S Gidding, Lori Laffel, Ingrid Libman, Laura Pyle, William V, Sherida Tollefsen, Ruth S Weinstock, Phil Zeitler, TODAY Study Group, Jane Lynch, Laure El, Lynda Fisher, Samuel S Gidding, Lori Laffel, Ingrid Libman, Laura Pyle, William V, Sherida Tollefsen, Ruth S Weinstock, Phil Zeitler

Abstract

Objective: Among adolescents with type 2 diabetes, there is limited information regarding incidence and progression of hypertension and microalbuminuria. Hypertension and microalbuminuria assessments made during the TODAY clinical trial were analyzed for effect of treatment, glycemic control, sex, and race/ethnicity.

Research design and methods: A cohort of 699 adolescents, 10-17 years of age, <2 years duration of type 2 diabetes, BMI ≥ 85%, HbA1c ≤ 8% on metformin therapy, controlled blood pressure (BP), and calculated creatinine clearance >70 mL/min, were randomized to metformin, metformin plus rosiglitazone, or metformin plus intensive lifestyle intervention. Primary study outcome was loss of glycemic control for 6 months or sustained metabolic decompensation requiring insulin. Hypertension and microalbuminuria were managed aggressively with standardized therapy to maintain BP <130/80 or <95th percentile for age, sex, and height and microalbuminuria <30 μg/mg.

Results: In this cohort, 319 (45.6%) reached primary study outcome, and 11.6% were hypertensive at baseline and 33.8% by end of study (average follow-up 3.9 years). Male sex and higher BMI significantly increased the risk for hypertension. Microalbuminuria was found in 6.3% at baseline and rose to 16.6% by end of study. Diagnosis of microalbuminuria was not significantly different between treatment arms, sex, or race/ethnicity, but higher levels of HbA1c were significantly related to risk of developing microalbuminuria.

Conclusions: Prevalence of hypertension and microalbuminuria increased over time among adolescents with type 2 diabetes regardless of diabetes treatment. The greatest risk for hypertension was male sex and higher BMI. The risk for microalbuminuria was more closely related to glycemic control.

Trial registration: ClinicalTrials.gov NCT00081328.

Figures

Figure 1
Figure 1
Cumulative incidence curves for time to diagnosis of hypertension during TODAY by treatment group (A), occurrence of glycemic failure (B), race/ethnicity (C), and sex (D).
Figure 2
Figure 2
Cumulative incidence curves for time to diagnosis of microalbuminuria during TODAY by treatment group (A), occurrence of glycemic failure (B), race/ethnicity (C), and sex (D).

References

    1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–2539
    1. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832–1839
    1. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008;25(Suppl. 2):25–29
    1. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883–892
    1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159–2167
    1. Bogdanović R. Diabetic nephropathy in children and adolescents. Pediatr Nephrol 2008;23:507–525
    1. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369:1823–1831
    1. Zeitler P, Epstein L, Grey M, et al. TODAY Study Group Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74–87
    1. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med 2008;38:32–46
    1. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 1996;98:649–658
    1. Zeitler P, Hirst K, Pyle L, et al. TODAY Study Group A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–2256
    1. Bayliss G, Weinrauch LA, D’Elia JA. Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 2012;12:440–446
    1. Le-Ha C, Beilin LJ, Burrows S, et al. Oral contraceptive use in girls and alcohol consumption in boys are associated with increased blood pressure in late adolescence. Eur J Prev Cardiol. 11 July 2012 [Epub ahead of print]
    1. Koenigsberg J, Boyd GS, Gidding SS, Hassink SG, Falkner B. Association of age and sex with cardiovascular risk factors and insulin sensitivity in overweight children and adolescents. J Cardiometab Syndr 2006;1:253–258
    1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–232
    1. Mayer-Davis EJ, Bell RA, Dabelea D, et al. SEARCH for Diabetes in Youth Study Group The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009;32(Suppl. 2):S99–S101
    1. Amed S, Dean HJ, Panagiotopoulos C, et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care 2010;33:786–791
    1. Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis 2006;48:720–726
    1. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001;138:481–485
    1. Savino A, Pelliccia P, Chiarelli F, Mohn A. Obesity-related renal injury in childhood. Horm Res Paediatr 2010;73:303–311
    1. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86:444–456
    1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288–296
    1. Hsu CC, Chang HY, Huang MC, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. Diabetes Care 2011;34:982–987
    1. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012;35:1265–1271
    1. Ninomiya T, Perkovic V, de Galan BE, et al. ADVANCE Collaborative Group Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813–1821
    1. Rossi MC, Nicolucci A, Pellegrini F, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008;23:1278–1284
    1. Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. QJM 2009;102:799–806
    1. Bell DS. Hypertension and diabetes: a toxic combination. Endocr Pract 2008;14:1031–1039
    1. Burgert TS, Dziura J, Yeckel C, et al. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. Int J Obes (Lond) 2006;30:273–280
    1. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012;380:601–610
    1. Anderson BJ, Edelstein S, Abramson NW, et al. TODAY Study Group Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care 2011;34:2205–2207

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir